N1A.F NAVAMEDIC ASA NK 1
- Market cap
- EUR 23.6M
- P/E
- -
- P/B
- 0.79x
- ROE
- -5.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is N1A.F undervalued?
Graham numberThe Graham number of NAVAMEDIC ASA NK 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NAVAMEDIC ASA NK 1 fundamental analysis
No fundamental analysis for NAVAMEDIC ASA NK 1 yet.
NAVAMEDIC ASA NK 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NAVAMEDIC ASA NK 1
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinur…
Full company profileNAVAMEDIC ASA NK 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NAVAMEDIC ASA NK 1 annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 278M | 382M | 512M | 531M | 565M | 557M |
| Gross Profit | 112M | 164M | 199M | 209M | 220M | 217M |
| Operating Income | 11.5M | 44.4M | 39.6M | 31.8M | 16.3M | -3.86M |
| EBITDA | - | 50.4M | 30.9M | 23.1M | 30.3M | 40.5M |
| Net Income | 618K | 29.4M | -13.7M | -5.49M | -23.5M | -17.2M |
| EPS | 0.04 | 1.68 | -0.78 | -0.31 | -0.98 | -0.72 |
| Balance Sheet | ||||||
| Total Assets | 330M | 383M | 507M | 467M | 742M | 657M |
| Total Liabilities | 179M | 173M | 302M | 251M | 408M | 351M |
| Shareholders' Equity | 151M | 210M | 205M | 217M | 334M | 306M |
| Cash & Short-term Investments | 51.7M | 54.3M | 36.9M | 36.1M | 72.6M | 53.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.30M | 17.9M | 2.18M | 39.4M | 25.6M | 13.9M |
| Capital Expenditure | 728K | 2.25M | 2.20M | 3.33M | 2.38M | 1.39M |
| Free Cash Flow | -2.03M | 15.7M | -19.0K | 36.0M | 23.2M | 12.5M |
| Ratios | ||||||
| ROE | 0.4% | 14.0% | -6.7% | -2.5% | -7.0% | -5.6% |
| ROA | 0.2% | 7.7% | -2.7% | -1.2% | -3.2% | -2.6% |
| Net Profit Margin | 0.2% | 7.7% | -2.7% | -1.0% | -4.2% | -3.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NAVAMEDIC ASA NK 1 dividends
NAVAMEDIC ASA NK 1 has not paid dividends in the last 5 fiscal years.
Who owns NAVAMEDIC ASA NK 1
- Insiders 69.50%
- Institutions 15.36%
- Public & others 15.14%
- Shares outstanding 24.0M
- Free float 9.97M
NAVAMEDIC ASA NK 1 company profile
- Company name
- NAVAMEDIC ASA NK 1
- Ticker
- N1A.F
- ISIN
- NO0010205966
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 38
- Fiscal year end
- December
- Address
- Henrik Ibsens gate 100, Oslo, Norway, 0255
- Phone
- 47 67 11 25 40
- Website
- navamedic.com
About NAVAMEDIC ASA NK 1
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, nutritional support, and ketogenic diet. In addition, it provides consumer health products consisting of non-prescription drugs and health care products for erectile dysfunction, pain, gastro-related problems, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.
NAVAMEDIC ASA NK 1 management
8- Mr. Lars MinorChief Executive Officer · born 1970
- Mr. Nils Ole KreklingChief Financial Officer
- Mr. Alexander LidmejerChief Operating Officer · born 1981
- Pal Zimmermann VonenDirector of Group Accounting
- Ms. Astrid J. Torgersen BratvedtChief Scientific Officer
- Annika PaloDirector of QA, Compliance & Sustainability
- Mr. Ole Henrik EriksenChief Business Development Officer · born 1960
- Nina MasvaerCommercial Director of Nordics & Head of Rx